DexCom, Inc. (NASDAQ:DXCM) Chairman Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $55.91, for a total value of $559,100.00. Following the sale, the chairman now owns 484,559 shares in the company, valued at approximately $27,091,693.69. The sale was disclosed in a filing with the SEC, which is available through this link.
DexCom, Inc. (NASDAQ DXCM) opened at $57.13 on Wednesday. DexCom, Inc. has a 52 week low of $42.62 and a 52 week high of $86.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. The firm has a market capitalization of $4,983.03, a P/E ratio of -100.23 and a beta of 0.21.
A number of hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its stake in DexCom by 12.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares during the period. Advisor Group Inc. raised its stake in DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares during the period. Amalgamated Bank raised its stake in DexCom by 5.7% during the 4th quarter. Amalgamated Bank now owns 17,107 shares of the medical device company’s stock worth $982,000 after buying an additional 924 shares during the period. Wedbush Securities Inc. raised its stake in DexCom by 24.2% during the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after buying an additional 1,089 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in DexCom by 0.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock worth $6,247,000 after buying an additional 1,095 shares during the period.
Several equities research analysts recently commented on the company. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. BidaskClub lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 22nd. Oppenheimer set a $67.00 target price on DexCom and gave the company a “buy” rating in a research report on Monday, February 12th. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Monday, November 6th. Finally, Morgan Stanley cut their target price on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom presently has an average rating of “Hold” and a consensus price target of $67.44.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/21/dexcom-inc-dxcm-chairman-terrance-h-gregg-sells-10000-shares.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.